{"corpus_id":22471512,"paper_sha":"a8a8d26f251f5b1b60272c70448921d352f50dd8","doi":"10.1097/JCP.0000000000000827","arxiv_id":null,"pmid":29232310,"pmcid":"5737453","mag_id":2774761407,"dblp_id":null,"acl_id":null,"title":"Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients","year":2017,"publication_date":"2017-12-01","venue":"Journal of Clinical Psychopharmacology","journal":{"name":"Journal of Clinical Psychopharmacology","pages":"19 - 26","volume":"38"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle"],"pubmed_pub_types":["Comparative Study","Journal Article","Multicenter Study"],"s2_fields_of_study":["Medicine","Psychology"],"reference_count":30,"citation_count":9,"influential_citation_count":0,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Antipsychotic Agents","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D014150"},{"d":"Cohort Studies","mj":false,"ui":"D015331"},{"d":"Delayed-Action Preparations","mj":false,"ui":"D003692"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Follow-Up Studies","mj":false,"ui":"D005500"},{"d":"France","mj":false,"ui":"D005602"},{"d":"Hospitalization","mj":false,"qs":[{"q":"statistics & numerical data","mj":false,"ui":"Q000706"}],"ui":"D006760"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Injections","mj":false,"ui":"D007267"},{"d":"Length of Stay","mj":false,"ui":"D007902"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Paliperidone Palmitate","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D000068882"},{"d":"Retrospective Studies","mj":false,"ui":"D012189"},{"d":"Risperidone","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D018967"},{"d":"Schizophrenia","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"}],"ui":"D012559"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"}],"chemicals":[{"n":"Antipsychotic Agents","ui":"D014150","reg":"0"},{"n":"Delayed-Action Preparations","ui":"D003692","reg":"0"},{"n":"Risperidone","ui":"D018967","reg":"L6UH7ZF8HC"},{"n":"Paliperidone Palmitate","ui":"D000068882","reg":"R8P8USM8FR"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-01/xeplion_ct_11046.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/a8a8d26f251f5b1b60272c70448921d352f50dd8","s2_open_access_license":"CCBYNCND","s2_open_access_status":"HYBRID","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Purpose/Background The study objective was to compare the impact of being treated by paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) on the length of stay on initial hospitalization, rehospitalization risk, and treatment duration in schizophrenic patients. Methods We conducted an observational retrospective cohort study in 43 centers in France, including schizophrenic patients who initiated a treatment by PP or RLAI during initial hospitalization. The follow-up periods started in September 2012 for the RLAI group (median follow-up duration, 233 days) and in June 2013 for the PP group (259 days). Statistical analyses were based on Cox regression models, with propensity score weighting to account for differences in patients’ characteristics. Findings/Results The analysis included 347 patients: 197 in the PP treatment group and 150 in the RLAI group. Compared with patients on RLAI, patients on PP were significantly more likely to have nonpsychiatric comorbidities, to have been on previous antipsychotic therapy, or to have been hospitalized for psychiatric care in the previous year. With regard to length of stay on initial hospitalization, there was no statistically significant difference between both groups (hazard ratio, 1.13 [0.97; 1.31]). Being on PP was associated with similar times to first rehospitalization compared with RLAI (hazard ratio, 0.92 [0.65; 1.30]). Implications/Conclusions We observed nonsignificant differences in initial hospitalization duration and time to rehospitalization between PP and RLAI, potentially due to lack of statistical power. A trend was observed in favor of PP with regard to time to treatment discontinuation, although this result was compromised by patients who switched between RLAI and PP.","claims":[{"public_id":"cl_5e51be55f0f32e5e213303d86849f7f6","status":"active","text":"A trend favored paliperidone palmitate for time to treatment discontinuation, but the result was affected by patients switching between the two injections.","confidence":0.9,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_5e51be55f0f32e5e213303d86849f7f6"},{"public_id":"cl_13bf3742a9d79d4a57b6fb82ac030fc9","status":"active","text":"No statistically significant difference was found between paliperidone palmitate and risperidone long-acting injection for length of stay on initial hospitalization.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_13bf3742a9d79d4a57b6fb82ac030fc9"},{"public_id":"cl_de239408f194f797039c894fde330f03","status":"active","text":"Patients receiving paliperidone palmitate were more likely than those receiving risperidone long-acting injection to have nonpsychiatric comorbidities, prior antipsychotic therapy, and psychiatric hospitalization in the previous year.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_de239408f194f797039c894fde330f03"},{"public_id":"cl_db7db9e0d2058d1b31b5c0da5f9991a4","status":"active","text":"Time to first rehospitalization was similar for paliperidone palmitate and risperidone long-acting injection.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_db7db9e0d2058d1b31b5c0da5f9991a4"}],"concepts":[{"public_id":"co_00bd6a8952537ead98fa23117cc1cb6a","status":"active","name":"risperidone long-acting injection","description":"A long-acting injectable form of risperidone used to treat schizophrenia.","types":["treatment"],"aliases":["RLAI"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_00bd6a8952537ead98fa23117cc1cb6a"},{"public_id":"co_06d4ed97355717dc865cf9fd30285e6d","status":"active","name":"time to first rehospitalization","description":"The interval from treatment initiation to the first subsequent hospital readmission.","types":["outcome"],"aliases":["rehospitalization risk"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_06d4ed97355717dc865cf9fd30285e6d"},{"public_id":"co_183b49a0d24ec5299a276ad2eea5f0c0","status":"active","name":"nonpsychiatric comorbidities","description":"Medical conditions other than psychiatric illness present in the patients.","types":["patient characteristic"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_183b49a0d24ec5299a276ad2eea5f0c0"},{"public_id":"co_315be32242a252a72e64a30091497054","status":"active","name":"time to treatment discontinuation","description":"The interval from treatment initiation until the injected antipsychotic was stopped.","types":["outcome"],"aliases":["treatment duration"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_315be32242a252a72e64a30091497054"},{"public_id":"co_584875fab598f3c3973fb7f4237ca5a0","status":"active","name":"propensity score weighting","description":"A statistical adjustment method used to balance differences in observed patient characteristics between treatment groups.","types":["statistical method"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_584875fab598f3c3973fb7f4237ca5a0"},{"public_id":"co_7e43474aa439ae987fe1919d114b405b","status":"active","name":"schizophrenic patients","description":"Patients diagnosed with schizophrenia who received one of the compared long-acting injections.","types":["population"],"aliases":["patients with schizophrenia"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7e43474aa439ae987fe1919d114b405b"},{"public_id":"co_a3bec6b817f73a0fee58aab6cc69dc54","status":"active","name":"prior antipsychotic therapy","description":"Antipsychotic medication use before initiation of the compared long-acting injection.","types":["patient characteristic"],"aliases":["previous antipsychotic therapy"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a3bec6b817f73a0fee58aab6cc69dc54"},{"public_id":"co_a734a466f0a6d7387b2edba947545df4","status":"active","name":"psychiatric hospitalization in the previous year","description":"A prior hospital admission for psychiatric care within the year before treatment initiation.","types":["patient characteristic"],"aliases":["hospitalized for psychiatric care in the previous year"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a734a466f0a6d7387b2edba947545df4"},{"public_id":"co_b988740565c9113ba7a829f0bd60cfc3","status":"active","name":"initial hospitalization","description":"The first hospitalization during which treatment with one of the long-acting injections was initiated.","types":["clinical event"],"aliases":["index hospitalization"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b988740565c9113ba7a829f0bd60cfc3"},{"public_id":"co_f0d0ea4dce60c057b41fdb303b0d2203","status":"active","name":"length of stay on initial hospitalization","description":"The duration of the initial hospital admission measured as an outcome.","types":["outcome"],"aliases":["hospital length of stay"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f0d0ea4dce60c057b41fdb303b0d2203"},{"public_id":"co_f6e73fab32fbc86b950c0bbd69368ddb","status":"active","name":"observational retrospective cohort study","description":"A nonrandomized cohort design using existing records to compare outcomes over follow-up.","types":["study design"],"aliases":["retrospective cohort study"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f6e73fab32fbc86b950c0bbd69368ddb"},{"public_id":"co_f9879daf722e2e6105ce76b421a0541d","status":"active","name":"paliperidone palmitate","description":"A long-acting injectable antipsychotic medication used to treat schizophrenia.","types":["treatment"],"aliases":["PP"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f9879daf722e2e6105ce76b421a0541d"}],"external_ids":{"DOI":"10.1097/JCP.0000000000000827","ArXiv":null,"PubMed":29232310,"PubMedCentral":"5737453","MAG":2774761407,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-01/xeplion_ct_11046.pdf","landing_url":"https://www.semanticscholar.org/paper/a8a8d26f251f5b1b60272c70448921d352f50dd8","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBYNCND","status":"HYBRID","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":633212,"paper_uid":"7998f257-bb16-41bf-8c04-0db0aa434141","canonical_identity":{"paper_id":633212,"paper_uid":"7998f257-bb16-41bf-8c04-0db0aa434141","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/22471512"}